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Abstract
Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi Sarcoma (KS), the most common cancer
diagnosed in HIV- infected patients. The role of neutralizing antibodies in KS pathogenesis and in KSHV infected individuals
is not clearly understood. The goal of this study was to investigate and compare the prevalence and titers of neutralizing
antibodies in plasma samples from KS patients and KSHV infected asymptomatic individuals from Zambia, a KS endemic
region in sub-Saharan Africa. Plasma samples (N= 267) consisting of KS patients (group 1) and asymptomatic individuals
(group 2) were collected from Lusaka, Zambia. A flow cytometry based quantitative neutralization assay utilizing
recombinant KSHV expressing GFP was used to detect KSHV neutralizing antibodies. Our results show that the overall
prevalence of neutralizing antibodies in KS patients (group 1) was 66.7% which was significantly higher than the prevalence
of 6.5% present in KSHV infected asymptomatic individuals (group 2). Total antibody titers as well as neutralizing antibodies
titers were found to be significantly higher among KS patients. It is likely that higher neutralizing antibodies prevalence and
titers in KS patients result from higher levels of antigenic stimulation over time. This study is first to compare prevalence and
titers of neutralizing antibodies in participants with and without disease from a KSHV endemic region.
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Introduction
Human herpesvirus-8 (HHV-8) also known as Kaposi’s
sarcoma-associated herpesvirus (KSHV) is the etiological agent
of Kaposi’s sarcoma (KS) and at least two other malignancies;
primary effusion lymphoma and multicentric Castleman’s disease
[1,2,3]. KS is a multifocal neoplasm characterized by angiogen-
esis, proliferation of spindle cells, edema and occasional dissem-
ination into visceral organs [4,5]. KS predominantly occurs in
immunosuppressed individuals and is one of the most common
malignancies associated with HIV infection. KSHV infection and
KS prevalence is low in general population in the US but is high in
endemic regions such as the ‘KS belt’ in sub-Saharan Africa.
Zambia is a part of the ‘‘KS belt’’ where KS is endemic and a
dramatic increase in the incidence of KS in adults and children has
also been reported with the advent of the HIV epidemic [6,7,8,9].
The fact that KSHV causes tumors in immunocompromised
patients underscores the importance of a functional immune
system in controlling KSHV infection. However, little is known
about the role of immune response in the development of KS,
especially in sub-Saharan Africa which is currently experiencing
an HIV epidemic.
Neutralizing antibodies are an important component of the
humoral immune response and have been implicated in control-
ling the progression of herpesvirus-associated disease [10]. Their
role in controlling KSHV infection and KSHV-associated disease
is still not clear. Till now there have been only two studies that
have investigated the prevalence and titers of neutralizing
antibodies in KS patients or in KSHV infected asymptomatic
individuals. Both reports have focused on a small number of KS
patients from the US. One has reported that KS patients had
lower titers of neutralizing antibodies compared to asymptomatic
individuals irrespective of their HIV status [11], while the other
study found no significant difference between the two groups [12].
In addition, the overall prevalence of neutralizing antibodies in KS
patients or asymptomatic subjects was found to be low and
comparable between the two groups [12]. A lack of comprehensive
studies makes it further more difficult to interpret the role of
neutralizing antibodies in KSHV infection, especially in popula-
tions where KS is endemic.
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We and other groups have earlier reported that in sub-Saharan
Africa, the seroprevalence of KSHV among adults is between 29%
to 48% which is relatively higher compared to the prevalence in
Western countries [13,14]. To date, there has not been any study
to investigate the prevalence of neutralizing antibodies in KS
patients or in KSHV infected asymptomatic subjects in an
endemic area. Whether the neutralizing antibody profile in
endemic areas is similar to previous studies conducted in the US
is not known. Therefore, the aim of this study was to compare the
prevalence and titer of neutralizing antibodies against KSHV in
KS patients and in asymptomatic individuals in an endemic
region, Zambia.
Materials and Methods
Study Subjects
A total of 267 plasma samples collected from patients at
University Teaching Hospital, Lusaka, Zambia, were used in this
study. These plasma samples were divided into two groups based
on the presence or absence of clinical KS in the patients. Group 1
included plasma samples collected during 2011 from 36 KS
patients who were seropositive for KSHV. All patients were
clinically diagnosed with KS and the initial diagnosis was
confirmed by a biopsy report. Group 2 comprised of plasma
samples from 231 asymptomatic individuals with KSHV positive
serostatus but without clinical KS. These samples are a part of a
larger ongoing cohort study conducted from 2004 to 2009 to
investigate KSHV transmission within families and were collected
from caregivers who brought their child to the study clinic as
described previously [15]. Written informed consent was obtained
from all study participants. Additionally, KSHV seronegative
plasma samples from anonymous healthy blood donors from local
blood bank in Lincoln, NE were used for assay controls. The study
was approved by the Institutional Review Board of the University
of Nebraska-Lincoln and the ethics board of the University of
Zambia.
KSHV and HIV Serology
The KSHV serostatus of participants was determined by
monoclonal-enhanced immunofluorescence assay (mIFA) as de-
scribed previously [16]. All positive plasma samples were diluted
further and tested by mIFA to determine the total KSHV antibody
titer of each sample. mIFA involved the use of tetradecanoyl
phorbol acetate (TPA) stimulated BC-3 cells that were fixed and
permeabilized on to teflon coated slides. To reduce subjectivity in
observing specific fluorescence, slides were read independently by
two laboratory workers. TPA stimulated BC3 cell slides were used
to determine total KSHV titer because BC3 cells are latently
infected with KSHV and upon stimulation express all the KSHV
lytic genes.
The HIV-1 status was determined, as recommended by the
Zambian Ministry of Health, using HIV-1/HIV-2 Abbott
determine (Abbott Laboratories) and confirmed using Unigold
kit (Trinity Biotech).
Cell Culture and rKSHV.219 Production
Human embryonic kidney cell line, HEK293, was grown in
Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal calf serum. Vero cells stably expressing KSHV tagged
green fluorescent protein (Vero.219) were maintained in DMEM
containing 10% fetal calf serum, and puromycin (6 mg/ml) for
selection. HEK293 cells were purchased from ATCC, Manassas,
VA. Vero.219 cells were a kind gift of Dr Jeff Vieira (University of
Washington, Seattle) [17].
Recombinant KSHV expressing GFP (rKSHV.219) was pro-
duced and titered as described previously by stimulating latently
infected Vero.219 cells [17]. Briefly, Vero.219 cells were
stimulated with baculovirus expressing KSHV RTA at room
temperature for 4 hours. Vero.219 cells were further stimulated
with 1.25 mM sodium butyrate in medium supplemented with
puromycin for 24 hours. The medium was replaced with fresh
medium after 24 hrs. Supernatant containing virus was collected
72 hours post stimulation, filtered and stored in the vapor phase of
liquid nitrogen. To titer rKSHV.219 virus, 293 cells were grown to
70–80% confluency in 96 well plates. The supernatant containing
virus was diluted 7 times at 4 fold dilutions starting at a 1:12
dilution. The diluted virus was added to 293 cells in triplicate wells
and incubated for 48 hours. The number of cells expressing GFP
in each well was counted using a fluorescent microscope. The titer
was calculated using the Spearman-Karber formula. Viral titers of
up to 105 infectious units/ml were used for neutralization assay.
Neutralization Assay
Neutralization assay was performed based on the method
previously described by Kimball et al but with some modifications
[11]. Neutralization assay was carried out in triplicate wells of 96-
well culture plates. Briefly, heat inactivated plasma (56uC for
30 min) was incubated at a 1:50 dilution with rKSHV.219 virus
for 1 hr at 37uC. Pre-plated 293 cells were infected with virus-
plasma mixture, centrifuged (4006g, 20 minutes) and subsequently
incubated at 37uC for 72 hours. The level of infection was
monitored by the number of cells expressing GFP using an
inverted fluorescent microscope and quantitated using a flow
cytometer (BD Biosciences) 72 hours post infection. A plasma
sample was considered positive for the presence of neutralizing
antibodies when 50% or higher inhibition in infectivity was
observed as compared to negative control plasma.
Plasma samples that were positive for neutralizing antibodies
were further titrated by 2-fold dilution starting at 1:50 to 1:800.
IC50 (50% of inhibitory concentration) was calculated using
GraphPad Prism version 5.05 (La Jolla, CA). Fluorescence images
from neutralization assay of two representative samples from
group I (ID#175 had lower and ID#138 had higher neutralizing
antibody titer) along with their parallel scatter plots are shown in
Figure 1. With increasing serial dilution of plasma, viral infectivity
(indicated by cells expressing GFP) increased and gradually
approached to that of the input virus or virus incubated with
KSHV negative plasma. The level of viral infectivity in the
presence of KSHV negative plasma was similar to that of input
virus (without plasma). No significant difference was observed in
the number of cells expressing GFP, with increasing dilution of
KSHV negative plasma (data not shown).
To ensure that the inhibition is antibody mediated and is not
due to a non-specific inhibitory factor that may have inhibited
KSHV infection. IgG antibodies were specifically depleted from
the plasma by incubating it with protein G sepharose beads
overnight (Figure 2). The ability of IgG depleted plasma to
neutralize rKSHV.219 virus was carried out by neutralization
assay as described above. No significant difference was observed in
the level of viral inhibition between IgG depleted and non-
depleted KSHV negative plasma. The level of viral inhibition in
the presence of IgG depleted KSHV positive plasma were similar
to those of the non-depleted and depleted KSHV negative plasma.
With the KSHV positive plasma, viral inhibition was markedly
reduced with increasing plasma dilution.
KSHV Neutralizing Antibodies
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Evaluation of Data and Statistical Analysis
Neutralization assay was performed in triplicate and a sample
was designated positive or negative (at plasma dilution 1:50) for the
presence of neutralizing antibodies if similar results were obtained
the first two times the assay was performed. Initially, each sample
was tested twice and the result was considered indeterminate if
concordant results were not observed. Subsequently, the assay was
repeated a third time. Based on the third result the sample was
considered positive or negative. None of the samples in group 1
were tested a third time because 100% concordance was achieved
in all the samples. In group 2, 9 out a total of 231 samples were
tested a third time because concordant results were not observed
after duplicate testing.
Average percent infectivity was calculated and a positive
neutralizing antibody outcome was defined as $50% reduction
in infectivity as compared to the KSHV seronegative control
plasma. To determine percent inhibition of viral infection, sample
data was normalized to input virus infection and calculated as:
Normalized Percent Infectivity = (Sample percent infectivity/Virus
only percent infectivity)6100. The percent inhibition was calcu-
lated as: (100 minus normalized percent infectivity). To calculate
neutralizing antibody titers, the inverse values of the last positive
dilution were transformed into log2 values and geometric mean
titers (GMT) were calculated for each group. P-values were
calculated using Mann-Whitney test.
The difference in prevalence of neutralizing antibodies was
measured by chi-square test or Fisher’s exact test. Correlation
coefficient between neutralizing antibody titers and total KSHV
antibody titers were calculated using SAS (v9.2) (PROC CORR).
All tests were 2-tailed and p-values ,0.05 were considered
significant. Power and sample size estimation was done using
Sample Power 2 (SPSS). All other statistical analyses were
performed using GraphPad Prism (v5.05) and SPSS (v19).
Results
Characteristics of Study Cohort
Table 1 summarizes the characteristics of the study population
(N = 267) that was divided into two groups. Briefly, all group 1
patients (n = 36) had clinical KS and were also seropositive for
HIV. The median CD4 T cell count and HIV viral load was 157
cells/mm3 and 143 copies/ml of plasma, respectively. Group 2
(n = 231) comprised of KSHV seropositive asymptomatic individ-
uals. The HIV-1 seroprevalence among this group was 46.7% and
the median CD4 T cell count of HIV positive individuals (n = 108)
was 319 cells/mm3. HIV viral load was not available for this group
of subjects due to unavailability of viral load testing in Zambia at
the time of study sample collection. The median age for both these
groups was comparable with median age of 33 years for group 1
and 31 years for group 2 samples.
Prevalence of Neutralizing Antibodies
As shown in Table 2 and Figure 3A, the overall prevalence of
neutralizing antibodies in group 1 (KS samples) was 66.7% (24/
36) and in group 2 (asymptomatic individuals) was 6.5% (15/231)
(p-value ,0.001). Table 2 compares the study participant
characteristics of samples that were positive for neutralizing
antibodies in group 1 vs. group 2. We did not observe an
association between gender and the presence of neutralizing
antibodies in group 1 vs. 2 samples (p-value = 0.18). However, we
observed a significant association between age and the prevalence
of neutralizing antibodies in group 1 vs. group 2 samples (p-
value = 0.004). In group 1, a majority of neutralizing antibody
positive patients were older (.30 years) but in group 2, there was
no association between age and the prevalence of neutralizing
antibodies. We observed neutralizing antibodies in 4/108 (3.7%)
HIV positive asymptomatic individuals as compared to 11/123
(8.9%) HIV negative asymptomatic individuals. Overall, the
neutralizing antibody prevalence was found to be significantly
higher in KS patients as compared to asymptomatic individuals
but we could not directly compare group 1 and 2 samples based on
the HIV status because all samples in group 1 were HIV positive.
We also could not compare the neutralizing antibody positive
Figure 1. KSHV Neutralization Assay. Fluorescent pictographs of
293 cells infected with rKSHV.219 incubated with serially diluted plasma
samples (1:50, 1:100, 1:200 and 1:800) from two Kaposi’s sarcoma
patients (ID 138 and 175) who were neutralizing antibody positive. ID
138 had comparatively higher titer neutralizing antibodies as compared
to ID 175. Parallel flow cytometry scatter plots are also presented.
Negative control (KSHV and KS negative plasma at a dilution of 1:50)
and virus only control are shown at extreme right.
doi:10.1371/journal.pone.0071254.g001
Figure 2. KSHV inhibition is antibody mediated. IgG antibodies
from KSHV positive and negative plasma were depleted using protein G
sepharose beads. Plasma was serially diluted and incubated with
rKSHV.219 before infecting 293 cells. Percent inhibition at each plasma
dilution was calculated by normalizing sample infectivity to infection
with virus in the absence of plasma.
doi:10.1371/journal.pone.0071254.g002
KSHV Neutralizing Antibodies
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samples between group 1 and 2 based on CD4 counts because of
incomplete data for group 2 samples.
Since there was a significant difference in the prevalence of
neutralizing antibodies in group 1 and group 2 samples, all
neutralizing antibody positive samples were further titrated to
investigate whether there were differences in the neutralizing
antibody titers within these groups. Figure 3B compares the GMT
of neutralizing antibodies of all samples in group 1 and 2 that had
detectable neutralizing antibodies. This data clearly demonstrates
that the GMT of neutralizing antibodies in group 1 (KS samples)
was significantly higher as compared to group 2 (asymptomatic
individuals) (p = 0.001). We also compared the neutralizing
antibody titers in males vs. females in each group and found no
significant difference between them (data not shown).
Total KSHV antibody titers were also determined for the entire
panel of 267 samples to investigate whether neutralizing antibody
titers were associated with total KSHV antibody titers. Figure 4A
compares the total KSHV antibody titers of all the subjects in
group 1 and group 2. It is clear that GMT of KSHV antibodies in
group 1 samples were significantly higher as compared to group 2
samples (p-value ,0.001). KSHV antibody titers in samples
positive for neutralizing antibodies (n = 39, 24 in group 1 and 15 in
group 2) were also compared to samples that did not have
detectable neutralizing antibodies (n = 228). This analysis revealed
Table 1. Characteristics of the study population.
Group 1 Group 2
Characteristic
(KS Samples)
n (%)
(Asymptomatic Individuals)
n (%)
Total Number 36 231
Gender
Male 23 (63.9) 104 (45.0)
Female 13 (36.1) 127 (55.0)
Median Age (years) 33 31
HIV Status
Positive 36 (100) 108 (46.7)
Negative 0 123 (53.3)
Median CD4 Count (Range) 157 (0–1116) 319 (42–1100)
Median HIV viral load (Range) 143 (50–100,000) NA
NA – Data not available.
doi:10.1371/journal.pone.0071254.t001
Table 2. Study population characteristics: Comparison of samples who elicited a neutralizing antibody response in group 1 and
group 2.
Neutralizing Antibodies Present in
Characteristic
Group 1
(KS Samples)
Number positive/total (%)
Group 2
(Asymptomatic Individuals)
Number positive/total (%) p-value**
Total 24 15
Gender 0.18
Male 17/23 (73.9) 7/104 (6.7)
Female 7/13 (53.8) 8/127 (6.3)
Age* 0.004
#30 years 3/12 (25.0) 9/113 (7.9)
.30 years 20/23 (87.0) 6/118 (5.1)
HIV Status ND
Positive 24/36 (66.7) 4/108 (3.7)
Negative 0 11/123 (8.9)
CD4 Count* ND
#200 cells/mm3 14/22 (6.4) 4/20 (20.0)
.200 cells/mm3 8/12 (66.7) 0/64
*Some participant characteristics had missing values.
**p value from chi-square test of overall association between sample type (group 1 vs. group 2) and study participant characteristics.
ND – Not determined.
doi:10.1371/journal.pone.0071254.t002
KSHV Neutralizing Antibodies
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that GMT of KSHV antibodies in neutralizing antibody positive
samples were also significantly higher as compared to samples that
had no detectable neutralizing antibodies (p-value ,0.001)
(Figure 4B). Correlation between neutralizing antibody titers and
total KSHV antibody titers was also determined and revealed a
positive correlation between the two titers (correlation coeffi-
cient = 0.47). This positive correlation was also present when
samples from each group were tested alone (correlation coefficient
for group 1 = 0.33 and for group 2 = 0.40).
Discussion
This is the first study to compare the prevalence and titers of
neutralizing antibodies in plasma samples from KS patients and
asymptomatic individuals from an endemic area. In the current
study we have used a modified version of a previously reported
infectivity assay to detect neutralizing antibodies against KSHV.
This assay utilizes a GFP-tagged recombinant KSHV and employs
flow cytometry to quantitate the infected cells as a readout system.
The quantitative strength of our flow cytometry-based neutraliza-
tion assay gave us an accurate and high throughput measure of the
neutralizing antibody titers of infected individuals. To achieve
high specificity, we defined plasma neutralization as 50% or higher
inhibition in infectivity compared to control plasma which was
KSHV negative.
The findings of this study clearly show that the prevalence and
titers of neutralizing antibodies in group 1 (KS patients) were
significantly higher as compared to group 2 (asymptomatic
individuals) (Figure 3A). Our findings are different from the study
reported by Kimball et al who demonstrated that patients in the
US diagnosed with AIDS-KS display lower titers of neutralizing
antibodies despite having higher levels of anti-KSHV antibodies
[11]. This difference could be attributed to different study
populations that have vastly different KSHV prevalence in the
general population. Our previous research in Zambia with the
same study population has shown that children get infected with
KSHV at a very early age, in contrast to the situation in US where
the seroprevalence of KSHV during childhood is very low. It is
likely that neutralizing antibody titer increases over the course of
KSHV infection and this increase is driven by higher levels of
antigenic stimulation i.e. viral load as has been previously reported
in KS patients [18,19,20]. We hypothesize that infection at an
early age followed by intermittent reactivation of latent virus over
time may result in extended exposure to viral antigens in an
endemic population. Also, it would provide time for the expansion
of B-cells producing neutralizing antibodies as the maturation of
humoral response against KSHV occurs in the infected individual.
Recent studies investigating the determinants of neutralizing
antibody response in HIV infection support the idea that
production of neutralizing antibodies requires continuous anti-
genic stimulation and usually take years [21,22].
Our finding that KS patients have high prevalence and
increased titers of neutralizing antibodies should not be interpreted
to mean that neutralizing antibodies are not protective in case of
KSHV infection. It is quite possible that neutralizing antibodies
have very different roles during primary KSHV infection and later
on during persistent long term infection. In chronically infected
patients neutralizing antibodies may have a limited role only in
controlling the spread of virus. However during primary infection,
neutralizing antibodies can prevent KSHV infection if they are
present at the time of exposure as would be the case if elicited by a
vaccine prior to primary infection. A prophylactic vaccine that can
Figure 3. Prevalence and titer of KSHV neutralizing antibodies
in group 1 and 2 samples. A: Percent prevalence of neutralizing
antibodies in group 1 (KS samples) and group 2 (asymptomatic
individuals). B: KSHV neutralizing antibody titers (log2 transformed) in
samples from group 1 (KS samples) and group 2 (asymptomatic
individuals) participants. GMT of neutralizing antibodies in each group
is also marked.
doi:10.1371/journal.pone.0071254.g003
Figure 4. Total KSHV antibody titers in samples. Comparison of
total KSHV antibody titer (log2 transformed) in; A: samples from group
1 (KS samples) and group 2 (asymptomatic individuals) participants and;
B: all samples that have neutralizing antibody present or absent. GMT
of KSHV antibody titers in each group is also marked.
doi:10.1371/journal.pone.0071254.g004
KSHV Neutralizing Antibodies
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strongly induce neutralizing antibodies could be useful to prevent
infection in KSHV endemic populations.
It is well established that HIV-infected individuals are at a
significantly higher risk for developing KS as opposed to HIV-1
negative individuals [23]. KSHV seroprevalence is highest among
individuals who are HIV infected compared to uninfected
individuals [24]. A recent study has shown that active replication
of KSHV was significantly associated with a low number of
CD4+cells in HIV positive antiretroviral therapy-naı¨ve males, thus
confirming the importance of immune response in controlling
KSHV replication [25]. Thus far, no correlation has been
reported between the prevalence of KSHV neutralizing antibodies
and HIV status of asymptomatic individuals. Unfortunately, the
number of neutralizing antibody positive individuals from HIV+
and HIV- asymptomatic individuals (group 2) were too small to
establish a meaningful correlation. The association between
neutralizing antibodies and HIV status needs to be studied in a
larger cohort of asymptomatic individuals.
It has been reported previously that the titer of KSHV
antibodies is higher in KS patients as compared to patients who
are KSHV infected asymptomatic patients [26,27]. We observed
similar results in the present study that the GMT of KSHV
antibodies were significantly higher in group 1 as compared to
group 2 (Figure 4A). Moreover, we observed that the KSHV
antibody titers in samples which had detectable neutralizing
antibodies were significantly higher as compared to samples that
did not have neutralizing antibodies (Figure 4B). We also observed
a positive correlation between KSHV antibody titers and
neutralizing antibody titers. This supports our hypothesis that
there is a slow maturation of the immune response against KSHV,
over a period of time to result in a concurrent increase in both
neutralizing antibody titers and KSHV antibody titers.
A limitation of this study was a lack of KSHV viral load
information due to limited availability of plasma samples. Also the
cross-sectional design of our study makes it difficult to predict the
duration and levels of neutralizing antibody response over a period
of time. Although hard to execute, a longitudinal follow up of
infected individuals would provide clues about the existence of a
temporal relationship between viral load and neutralizing antibody
response. It would be equally important to investigate the kinetics
of neutralizing antibody response from the time of seroconversion
to KS diagnosis and determine whether neutralizing antibodies
against KSHV can serve as prognostic markers for disease
progression.
In summary, by using a standardized quantitative neutralization
assay we have the investigated the prevalence and titers of
neutralizing antibodies in KS patients and asymptomatic individ-
uals from an endemic region. To our knowledge, this is first study
of its kind from a KS endemic region. Our results show that there
is low prevalence of neutralizing antibodies in asymptomatic
individuals, in contrast to high prevalence and higher titers of
neutralizing antibodies in KS patients. In future, we plan to
investigate the development of neutralizing antibodies on a larger
longitudinal cohort to better define the role of neutralizing
antibodies in the pathogenesis of KSHV and the development of
KS.
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